Literature DB >> 3457610

Estrone sulfate: a potential source of estradiol in human breast cancer tissues.

S J Santner, D Leszczynski, C Wright, A Manni, P D Feil, R J Santen.   

Abstract

Local formation of estradiol in human breast tumors could provide a more important source of estrogen than is delivered from plasma. Prior studies have suggested that estrone is primarily synthesized from estrone sulfate. The enzyme 17 beta-hydroxysteroid dehydrogenase (HSD) would be required to convert estrone to estradiol. This study characterized HSD in 1000 X g supernatants from human breast tumors. Estradiol synthesis was linearly related to tissue concentration or time over the range studied. Cofactor requirements varied with estrone concentration. High and low affinity sites were found in 50% of tissues studied, while the remainder contained only low affinity sites. Screen assays showed measurable activity in all 42 samples tested. This activity ranged from 0.73- greater than 100 nmol estrone synthesized/g protein/hr, with a median activity of 5.9 nmol/g/hr. We evaluated the biological relevance of the sulfatase-HSD pathway by testing the ability of estrone sulfate to stimulate colony formation in soft agar cultures of nitrosomethylurea-induced rat mammary tumors. The maximally effective concentration ranged from 10(-7) to 10(-4)M. Significant stimulation of colony formation was observed in 7 of 8 experiments. The estrone sulfate stimulation pattern was similar to that previously observed with estradiol. Of the 3H-estrone sulfate added to the dishes, 20-98% was recovered as estrone and 0.2-6% as estradiol. These studies suggest that the requisite enzymes are present in human breast tumors for conversion of estrone sulfate to estradiol, and that this pathway may be biologically significant.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3457610     DOI: 10.1007/BF01886734

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  35 in total

1.  Effects of plasma estrogen sulfates in mammary cancer cells.

Authors:  F Vignon; M Terqui; B Westley; D Derocq; H Rochefort
Journal:  Endocrinology       Date:  1980-04       Impact factor: 4.736

2.  Apparent immunologic nonidentity of human placental and endometrial 17beta-estradiol dehydrogenase.

Authors:  W Marovitz; A Loucopoulos; P G Satyaswaroop; E Gurpide; R Todd; F Naftolin
Journal:  Am J Obstet Gynecol       Date:  1980-11-15       Impact factor: 8.661

3.  Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content.

Authors:  M Edery; J Goussard; L Dehennin; R Scholler; J Reiffsteck; M A Drosdowsky
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

4.  Estrone and estradiol content in human breast tumors: relationship to estradiol receptors.

Authors:  J Fishman; J S Nisselbaum; C J Menendez-Botet; M K Schwartz
Journal:  J Steroid Biochem       Date:  1977-08       Impact factor: 4.292

5.  Polyamines as mediators of estrogen action on the growth of experimental breast cancer in rats.

Authors:  A Manni; C Wright
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

6.  Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.

Authors:  E Samojlik; R J Santen; T J Worgul
Journal:  Steroids       Date:  1982-05       Impact factor: 2.668

7.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.

Authors:  S J Santner; P D Feil; R J Santen
Journal:  J Clin Endocrinol Metab       Date:  1984-07       Impact factor: 5.958

Review 8.  Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.

Authors:  E Samojlik; J D Veldhuis; S A Wells; R J Santen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

9.  A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

Authors:  R J Santen; T J Worgul; E Samojlik; A Interrante; A E Boucher; A Lipton; H A Harvey; D S White; E Smart; C Cox; S A Wells
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

10.  Conversion of blood androgens to estrogens in normal adult men and women.

Authors:  C Longcope; T Kato; R Horton
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

View more
  19 in total

Review 1.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

Review 2.  Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells.

Authors:  J B Adams
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

Review 3.  Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women's health.

Authors:  Majorie B M van Duursen
Journal:  Toxicol Res (Camb)       Date:  2017-09-08       Impact factor: 3.524

Review 4.  The endocrine basis of benign breast disorders.

Authors:  L Dogliotti; F Orlandi; A Angeli
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

5.  Uterine estrogen sulfatase may play a more important role than the hepatic sulfatase in mediating the uterotropic action of estrone-3-sulfate.

Authors:  B T Zhu; J H Fu
Journal:  Endocrine       Date:  1997-10       Impact factor: 3.633

6.  Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4).

Authors:  Fanfan Zhou; Ling Zhu; Pei H Cui; W Bret Church; Michael Murray
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

7.  Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Authors:  Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry
Journal:  Breast Cancer Res Treat       Date:  2016-12-09       Impact factor: 4.872

8.  Steroid sulfatase and estrogen sulfotransferase in the atherosclerotic human aorta.

Authors:  Yasuhiro Nakamura; Yasuhiro Miki; Takashi Suzuki; Taisuke Nakata; Andrew David Darnel; Takuya Moriya; Chika Tazawa; Haruo Saito; Tadashi Ishibashi; Shoki Takahashi; Shogo Yamada; Hironobu Sasano
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

Review 9.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

10.  Dehydroepiandrosterone and estrone 17-ketosteroid reductases in MCF-7 human breast cancer cells.

Authors:  J H MacIndoe; M Hinkhouse; G Woods
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.